Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combo Product Office To Tackle Intercenter Agreements, “Chemical Action”

This article was originally published in The Gray Sheet

Executive Summary

FDA's final rule defining primary mode of action will be released within the next six months, Office of Combination Products Director Mark Kramer projected Jan. 11-12

You may also be interested in...



Combo Product Coalition Drafting Proposal On Regulatory Selection Criteria

The Combination Product Coalition plans to submit a policy paper to FDA by the end of the summer proposing criteria for determining applicable regulations at various points in a combo product's lifecycle

Combo Product Coalition Drafting Proposal On Regulatory Selection Criteria

The Combination Product Coalition plans to submit a policy paper to FDA by the end of the summer proposing criteria for determining applicable regulations at various points in a combo product's lifecycle

Final Combo Product Dispute Resolution Guidelines Largely Unchanged

FDA's final guidance on formal dispute resolutions for combination products provides additional details on when it is appropriate to file a complaint regarding the review time for a combo product submission

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel